scholarly journals Association of PEDF polymorphisms with age-related macular degeneration and polypoidal choroidal vasculopathy: a systematic review and meta-analysis

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Li Ma ◽  
Shu Min Tang ◽  
Shi Song Rong ◽  
Haoyu Chen ◽  
Alvin L. Young ◽  
...  
Keyword(s):  
Systematic Review ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Choroidal Vasculopathy

scholarly journals The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Yimin Wang ◽  
Mengxi Shen ◽  
Jinwei Cheng ◽  
Xiaodong Sun ◽  
Peter K. Kaiser
Keyword(s):  
Systematic Review ◽  
Polypoidal Choroidal Vasculopathy ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Random Effect ◽  
Fixed Effect Model ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Significant Difference ◽  
Choroidal Vasculopathy

Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (nAMD), has been well established in randomized clinical trials. This meta-analysis has evaluated the efficacy of a novel anti-VEGF agent, conbercept, in the management of PCV using ranibizumab and aflibercept as the reference agents. Methods. Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. Results. Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. Conclusions. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.

Sign in / Sign up

Export Citation Format

Share Document